Lane and colleagues investigated the selective PPAR-γ agonist pioglitazone (PIO) for preventing hypoxia-induced IUGR, demonstrating partial prevention of fetal growth restriction and attenuation of placental insufficiency. Here, PPARG is linked to fetal growth restriction.